Skip to content

Oxford Biomedica inks COVID-19 vaccine supply deal with AstraZeneca

September 1, 2020

Oxford Biomedica plc (OTCPK:OXBDF) has signed an 18-month supply agreement under a three-year master supply and development contract with AstraZeneca (NYSE:AZN) for the large-scale commercial manufacture of COVID-19 vaccine AZD1222.

By mutual agreement, the supply period may be extended for an additional 18 months.

Under the terms of the deal, AZN will pay Oxford £15M upfront as a capacity reservation fee. Assuming all goes according to plan, Oxford expects to receive more than £35M in additional revenue plus certain materials costs for the production of multiple large-scale batches of AZN1222 until year-end 2021.

Oxford will reserve capacity for AZN in up to three suites in the Group’s new 7,800 sq. meter manufacturing center, OxBox, for the initial 18-month period. The new GMP facility can accommodate up to 1,000-liter scale.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: